| Name | Werner syndrome RecQ helicase-IN-3 |
|---|---|
| Synonyms |
N-(2-chloro-4-(trifluoromethyl)phenyl)-2-(2-(3,6-dihydro-2H-pyran-4-yl)-5-ethyl-6-(4-(3-hydroxypicolinoyl)piperazin-1-yl)-7-oxo-[1,2,4]triazolo[1,5-a]pyrimidin-4(7H)-yl)acetamide
[1,2,4]Triazolo[1,5-a]pyrimidine-4(7H)-acetamide, N-[2-chloro-4-(trifluoromethyl)phenyl]-2-(3,6-dihydro-2H-pyran-4-yl)-5-ethyl-6-[4-[(3-hydroxy-2-pyridinyl)carbonyl]-1-piperazinyl]-7-oxo |
| Description | Werner syndrome RecQ helicase-IN-3 is a potent and orally active werner syndrome recQ helicase (WRN) inhibitor with an IC50 value of 0.06 µM. Werner syndrome RecQ helicase-IN-3 shows antiproliferative activity. Werner syndrome RecQ helicase-IN-3 shows anticancer activity[1]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 0.06 µM (WRN)[1] |
| In Vitro | Werner syndrome RecQ helicase-IN-3 (example 96) (0-10 µM; 8-20 days) 显示抗增殖活性,对 SW48,DLD1 WRN-KO 细胞的 GI50s 值分别为 0.06,>10 µM[1]。 Cell Proliferation Assay[1] Cell Line: SW48, DLD1 WRN-KO cells Concentration: 0-10 µM Incubation Time: 8-20 days Result: Showed antiproliferative activity with GI50s of 0.06, >10 µM for SW48, DLD1 WRN-KO cells, respectively. |
| In Vivo | Werner syndrome RecQ helicase-IN-3 (120 mg/kg; daily for 22 days) 在小鼠体内显示出抗癌活性[1]。 Animal Model: Female Crl:NU(NCr)-Foxn1nu -Homozygous nude mice (SW48 xenografts cells)[1] Dosage: 120 mg/kg Administration: P.o.; daily for 22 days Result: Inhibited tumor growth. |
| References |
| Molecular Formula | C31H30ClF3N8O5 |
|---|---|
| Molecular Weight | 687.07 |